Biology Reference
In-Depth Information
support cere-120 for Parkinson's disease.
Neurosurgery 64:602-612, discussion 612-3
23. Herzog CD et al (2008) Transgene expres-
sion, bioactivity, and safety of CERE-120
(AAV2-neurturin) following delivery to the
monkey striatum. Mol Ther 16:1737-1744
24. Herzog CD et al (2007) Striatal delivery of
CERE-120, an AAV2 vector encoding human
neurturin, enhances activity of the dopaminer-
gic nigrostriatal system in aged monkeys. Mov
Disord 22:1124-1132
25. Marks WJ Jr et al (2010) Gene delivery of
AAV2-neurturin for Parkinson's disease: a
double-blind, randomised, controlled trial.
Lancet Neurol 9(12):1164-1172
26. Bartus RT et al (2010) Bioactivity of AAV2-
neurturin gene therapy (CERE-120):
differences between Parkinson's disease and
nonhuman primate brains. Mov Disord
26(1):27-36
27. Jakobsson J et al (2003) Targeted transgene
expression in rat brain using lentiviral vectors.
J Neurosci Res 73:876-885
28. Krol J, Loedige I, Filipowicz W (2010) The wide-
spread regulation of microRNA biogenesis, func-
tion and decay. Nat Rev Genet 11: 597-610
29. Brown BD et al (2007) Endogenous
microRNA can be broadly exploited to regu-
late transgene expression according to tissue,
lineage and differentiation state. Nat
Biotechnol 25:1457-1467
30. Colin A et al (2009) Engineered lentiviral vec-
tor targeting astrocytes in vivo. Glia 57:
667-679
31. Deo M et al (2006) Detection of mammalian
microRNA expression by in situ hybridization
with RNA oligonucleotides. Dev Dyn 235:
2538-2548
32. Lagos-Quintana M et al (2002) Identifi cation
of tissue-specifi c microRNAs from mouse.
Curr Biol 12:735-739
33. Miller RM et al (2006) Robust dysregulation
of gene expression in substantia nigra and stri-
atum in Parkinson's disease. Neurobiol Dis 21:
305-313
34. Nakayama A et al (2003) Role for RFX tran-
scription factors in non-neuronal cell-specifi c
inactivation of the microtubule-associated pro-
tein MAP1A promoter. J Biol Chem 278:
233-240
35. Duty S, Jenner P (2011) Animal models of
Parkinson's disease: a source of novel treat-
ments and clues to the cause of the disease. Br
J Pharmacol 164:1357-1391
36. Hioki H et al (2007) Effi cient gene transduc-
tion of neurons by lentivirus with enhanced
neuron-specifi c promoters. Gene Ther 14:
872-882
37. Brown BD, Naldini L (2009) Exploiting and
antagonizing microRNA regulation for thera-
peutic and experimental applications. Nat Rev
Genet 10:578-585
38. Jakobsson J et al (2004) Lesion-dependent
regulation of transgene expression in the rat
brain using a human glial fi brillary acidic
protein-lentiviral vector. Eur J Neurosci 19:
761-765
39. Rosenblad C et al (2000) In vivo protection of
nigral dopamine neurons by lentiviral gene
transfer of the novel GDNF-family member
neublastin/artemin. Mol Cell Neurosci 15:
199-214
40. Ebert MS, Neilson JR, Sharp PA (2007)
MicroRNA sponges: competitive inhibitors of
small RNAs in mammalian cells. Nat Methods
4:721-726
Search WWH ::
Custom Search